Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Disappointing Provenge Sales Stir Doubts About Demand

This article was originally published in The Pink Sheet Daily

Executive Summary

Withdrawing sales forecast and suffering a major blow to stock price, Dendreon notes difficulty in reaching community doctors.

You may also be interested in...



Under Sanpower, Can Provenge Finally Have A Happy Ending?

Strategy of focusing immunotherapy on urologists and earlier stage prostate cancer is paying off, says CEO James Caggiano, as Dendreon becomes a standalone company under Chinese conglomerate Sanpower

Deal Watch: Valeant’s Financial/Commercial Strength Offers A New Chance For Provenge

AstraZeneca buys out respiratory franchise from Actavis, which it had gained a year prior with its purchase of Forest. Mylan announced two deals Feb. 2, collaborating in COPD with Theravance and buying women’s health products from India’s Famy Care.

Valeant To Buy Dendreon’s Never-Was Cancer Vaccine Provenge

The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel